AU2003210210A1 - The use of omega-3 polyunsaturated acids ethyl esters in patients suffering from heart failure - Google Patents
The use of omega-3 polyunsaturated acids ethyl esters in patients suffering from heart failureInfo
- Publication number
- AU2003210210A1 AU2003210210A1 AU2003210210A AU2003210210A AU2003210210A1 AU 2003210210 A1 AU2003210210 A1 AU 2003210210A1 AU 2003210210 A AU2003210210 A AU 2003210210A AU 2003210210 A AU2003210210 A AU 2003210210A AU 2003210210 A1 AU2003210210 A1 AU 2003210210A1
- Authority
- AU
- Australia
- Prior art keywords
- omega
- heart failure
- patients suffering
- ethyl esters
- acids ethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITMI2002A000269 | 2002-02-12 | ||
IT2002MI000269A ITMI20020269A1 (en) | 2002-02-12 | 2002-02-12 | USE OF OMEGA-3 POLYUNSATURATED ACID ETHYL STERES IN PATIENTS WITH HEART INSUFFICIENCY |
PCT/EP2003/001108 WO2003068216A1 (en) | 2002-02-12 | 2003-02-05 | The use of omega-3 polyunsaturated acids ethyl esters in patients suffering from heart failure |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2003210210A1 true AU2003210210A1 (en) | 2003-09-04 |
Family
ID=11449201
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2003210210A Abandoned AU2003210210A1 (en) | 2002-02-12 | 2003-02-05 | The use of omega-3 polyunsaturated acids ethyl esters in patients suffering from heart failure |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1474125A1 (en) |
AU (1) | AU2003210210A1 (en) |
IT (1) | ITMI20020269A1 (en) |
WO (1) | WO2003068216A1 (en) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9901809D0 (en) | 1999-01-27 | 1999-03-17 | Scarista Limited | Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes |
ITMI20022511A1 (en) * | 2002-11-26 | 2004-05-27 | Victorix Assets Ltd | USE OF PHARMACEUTICAL COMPOSITIONS CONTAINING ETHYL ESTERS OF OMEGA-3 POLYUNSATURATED ACIDS IN THE ORDER OF ATRIAL FIBRILLATION. |
GB0403247D0 (en) | 2004-02-13 | 2004-03-17 | Tillotts Pharma Ag | A pharmaceutical composition |
JP2009523414A (en) | 2005-12-21 | 2009-06-25 | ブルーディ、テクノロジー、ソシエダッド、リミターダ | Use of DHA, EPA or DHA-derived EPA to treat lesions associated with oxidative damage of cells |
ES2277557B1 (en) | 2005-12-21 | 2008-07-01 | Proyecto Empresarial Brudy, S.L. | USE OF DOCOSAHEXAENOIC ACID FOR THE TREATMENT OF OXIDATIVE CELL DAMAGE. |
JP5924834B2 (en) | 2008-09-02 | 2016-05-25 | アマリン ファーマシューティカルズ アイルランド リミテッド | Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and method of using this pharmaceutical composition |
SG173612A1 (en) | 2009-02-10 | 2011-09-29 | Amarin Pharma Inc | Use of eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia |
AU2010222648B2 (en) | 2009-03-09 | 2016-07-07 | Pronova Biopharma Norge As | Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof |
CN102458109B (en) | 2009-04-29 | 2015-02-11 | 阿马里纳制药公司 | Stable pharmaceutical composition and methods of using same |
RU2624506C2 (en) | 2009-04-29 | 2017-07-04 | АМАРИН КОРПОРЕЙШН ПиЭлСи | Pharmaceutical compositions containing epa and cardiovascular agents and their application methods |
PT2443246T (en) | 2009-06-15 | 2018-03-14 | Amarin Pharmaceuticals Ie Ltd | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
BR122019016628B8 (en) | 2009-09-23 | 2021-07-27 | Amarin Corp Plc | use of a composition comprising an atorvastatin hydroxy derivative or pharmaceutically acceptable salt thereof and an oil comprising ethyl eicosapentaenoate or ethyl docosahexaenoate for the manufacture of a medicament for the treatment of a cardiovascular disease |
US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
NZ744990A (en) | 2010-11-29 | 2019-10-25 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
WO2012108379A1 (en) | 2011-02-07 | 2012-08-16 | 持田製薬株式会社 | Therapeutic agent for diastolic congestive heart failure |
US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
EP2775837A4 (en) | 2011-11-07 | 2015-10-28 | Amarin Pharmaceuticals Ie Ltd | Methods of treating hypertriglyceridemia |
JP6307442B2 (en) | 2012-01-06 | 2018-04-04 | アマリン ファーマシューティカルス アイルランド リミテッド | Compositions and methods for reducing the level of high sensitivity (HS-CRP) in a subject |
KR20150036252A (en) | 2012-06-29 | 2015-04-07 | 애머린 파마슈티칼스 아일랜드 리미티드 | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
US20150265566A1 (en) | 2012-11-06 | 2015-09-24 | Amarin Pharmaceuticals Ireland Limited | Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy |
US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
WO2015195662A1 (en) | 2014-06-16 | 2015-12-23 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids |
US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
US10966951B2 (en) | 2017-05-19 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
SG11202102872QA (en) | 2018-09-24 | 2021-04-29 | Amarin Pharmaceuticals Ie Ltd | Methods of reducing the risk of cardiovascular events in a subject |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1308613B1 (en) * | 1999-02-17 | 2002-01-09 | Pharmacia & Upjohn Spa | ESSENTIAL FATTY ACIDS IN THE PREVENTION OF CARDIOVASCULAR EVENTS. |
ATE305810T1 (en) * | 2000-05-22 | 2005-10-15 | Pro Aparts Investimentos E Con | PHARMACEUTICAL COMPOSITION CONTAINING FATTY ACID WHICH IS AT LEAST 80 Wt. CONTAINS EPA AND DHA |
ITMI20010129A1 (en) * | 2001-01-25 | 2002-07-25 | Pharmacia & Upjohn Spa | ESSENTIAL FATTY ACIDS IN THE THERAPY OF HEART INSUFFICIENCY AND HEART FAILURE |
-
2002
- 2002-02-12 IT IT2002MI000269A patent/ITMI20020269A1/en unknown
-
2003
- 2003-02-05 WO PCT/EP2003/001108 patent/WO2003068216A1/en not_active Application Discontinuation
- 2003-02-05 EP EP03739455A patent/EP1474125A1/en not_active Withdrawn
- 2003-02-05 AU AU2003210210A patent/AU2003210210A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2003068216A1 (en) | 2003-08-21 |
ITMI20020269A0 (en) | 2002-02-12 |
EP1474125A1 (en) | 2004-11-10 |
ITMI20020269A1 (en) | 2003-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2003210210A1 (en) | The use of omega-3 polyunsaturated acids ethyl esters in patients suffering from heart failure | |
AU2003217759A1 (en) | Omega-3 fatty acids or omega-3 phosphatidylcholine in the treatment of depression | |
AU2003259904A1 (en) | Coated polyunsaturated fatty acid-containing particles and coated liquid pharmaceutical-containing particles | |
PL363269A1 (en) | Essential n-3 fatty acids in cardiac insufficiency and heart failure therapy | |
GB2409644B (en) | Formulation comprising eicosapentaenoic acid or an ester thereof and a triterpene or an ester thereof | |
AU2002224914A1 (en) | Method and device for the diagnosis and therapy of chronic heart failure | |
IL172170A0 (en) | Propionic acid derivatives useful in the treatment of lipid disorders | |
AU2003208920A1 (en) | Fatty acid-containing compositions and methods for the treatment of cytokine mediated disorders | |
AU2003201693A1 (en) | Non-aromatic 17.alpha.-esters of androstane-17.beta.-carboxylate esters as anti-inflammatory agents | |
AU9164198A (en) | Use of organic acid esters in dietary fat | |
HK1073650A1 (en) | Methods for producing substituted acrylic acid esters and use of the latter for producing substituted | |
IL151014A0 (en) | Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure | |
HK1059386A1 (en) | Potentiation of therapeutic effects of polyunsaturated fatty acids | |
EP1685218A4 (en) | Fatty acid esters and uses thereof | |
HK1072609A1 (en) | New etonogestrel esters | |
AU2003223930A1 (en) | Pharmaceutical use of boronic acids and esters thereof | |
AU2003208769A1 (en) | Methods for the production of unsaturated fatty acids | |
AU2003304576A1 (en) | Cis-hydrogenated fatty acid coating of medical devices | |
AU2003222083A1 (en) | Acid and ester compounds and methods of using the same | |
AU2003290799A1 (en) | 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | |
AU2003249191A1 (en) | Low polarity dimerate and trimerate esters as plasticizers for elastomers | |
HK1072568A1 (en) | Use of new etonogestrel esters | |
WO2005053669A8 (en) | Use of omega-3 polyunsaturated fatty acids for sleep apnoea | |
ITMI20022511A1 (en) | USE OF PHARMACEUTICAL COMPOSITIONS CONTAINING ETHYL ESTERS OF OMEGA-3 POLYUNSATURATED ACIDS IN THE ORDER OF ATRIAL FIBRILLATION. | |
AU2003226582A1 (en) | Use of beta-aminoisobutyric acid for the treatment of diseases linked to the accumulation of triglycerides and cholesterol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |